Literature DB >> 21995414

Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.

Young Kyung Yoon1, Eun Ju Kim, Byung Chul Chun, Joong Sik Eom, Dae Won Park, Jang Wook Sohn, Min Ja Kim.   

Abstract

BACKGROUND AND
OBJECTIVE: Community-acquired pneumonia (CAP) is generally considered to be a major cause of morbidity and mortality. There is much controversy regarding the optimal choice of antibiotics for patients with CAP. The aim of this study was to identify the antibiotics prescribed for adults hospitalized with CAP in Korea during a calendar year.
METHODS: This population-based, descriptive epidemiological study was performed using data from nationwide health insurance claims from 1 January 2004 to 31 December 2004. The study population was adults (≥18 years old), who had been hospitalized with CAP as determined by discharge diagnosis, and who had been treated with antibiotics for ≥3 days. The exclusion criteria were tuberculosis, underlying malignancies and potential nosocomial pneumonia, based on the department providing care, or surgery reports during the admission.
RESULTS: Of the 5592 adults hospitalized with CAP, data for 3662 (65.5%) patients was eligible for inclusion in the analysis. This included data for 1899 (51.9%) males, and 2045 (55.8%) patients ≥65 years of age. The most frequently prescribed antimicrobial regimen was β-lactam/β-lactamase inhibitors and fluoroquinolones in combination (31.0%), followed by β-lactam/β-lactamase inhibitors plus macrolides (30.2%), monotherapy (17.0%), β-lactam/β-lactamase inhibitors plus aminoglycosides (12.9%), β-lactam/β-lactamase inhibitors plus clindamycin (4.9%), and cephalosporins plus fluoroquinolones (2.5%). Monotherapy included, in decreasing order of use, cephalosporins (6.0%), fluoroquinolones (3.5%), β-lactam/β-lactamase inhibitors (2.3%) and macrolides (2.2%).
CONCLUSIONS: In this study, patterns of antimicrobial prescription for patients hospitalized with CAP were assessed for the first time in Korea. There was divergence from the 2009 Korean guidelines for the treatment of CAP, reinforcing the need for assessment of physicians' adherence to the guidelines.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21995414     DOI: 10.1111/j.1440-1843.2011.02077.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  5 in total

Review 1.  Year in review 2012: lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Kazuhisa Takahashi; Pyng Lee
Journal:  Respirology       Date:  2013-04       Impact factor: 6.424

2.  Trend of Antibiotic Usage for Hospitalized Community-acquired Pneumonia Cases in Korea Based on the 2010-2015 National Health Insurance Data.

Authors:  Bongyoung Kim; Rangmi Myung; Myoung Jae Lee; Jieun Kim; Hyunjoo Pai
Journal:  J Korean Med Sci       Date:  2020-12-07       Impact factor: 2.153

3.  Continuing Quality Assessment Program Improves Clinical Outcomes of Hospitalized Community-Acquired Pneumonia: A Nationwide Cross-Sectional Study in Korea.

Authors:  Tai Joon An; Jun-Pyo Myong; Yun-Hee Lee; Sang Ok Kwon; Eun Kyung Shim; Ji Hyeon Shin; Hyoung Kyu Yoon; Sung Hwan Jeong
Journal:  J Korean Med Sci       Date:  2022-08-01       Impact factor: 5.354

4.  A 2011-2012 survey of doctors' perceptions of korean guidelines and empirical treatment of community-acquired pneumonia.

Authors:  Hye-In Kim; Shin-Woo Kim; Hyun-Ha Chang; Jong-Myung Lee; Kyong Ran Peck
Journal:  Infect Chemother       Date:  2013-12-27

5.  Prescription of Antibiotics for Adults with Acute Infectious Diarrhea in Korea: A Population-based Study.

Authors:  Hyo Jin Lee; Ki Ho Park; Dong Ah Park; Joonhong Park; Byoung Wook Bang; Seung Soon Lee; Eun Jung Lee; Youn Jeong Kim; Sung Kwan Hong; Yang Ree Kim
Journal:  Infect Chemother       Date:  2019-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.